Early Onset of Response to Fremanezumab in Migraine Patients With Moderate to Severe Depression and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study (4289) | Publicación